Fukano Kento, Watashi Koichi
Department of Virology II, National Institute of Infectious Diseases.
Department of Analytical Biochemistry, Meiji Pharmaceutical University.
Yakugaku Zasshi. 2019;139(1):81-87. doi: 10.1248/yakushi.18-00164-4.
The development of antiviral agents enables the control of chronic infectious diseases caused by infection with herpesviruses, human immunodeficiency virus, and hepatitis C virus. In contrast, antiviral treatment against hepatitis B virus (HBV) infection remains a significant area for improvement. One of the main barriers hampering the progress of HBV research has been a lack of cell culture systems efficiently reproducing the viral proliferation process. Recently, cell line-based HBV infection systems have been developed which are useful to analyze the mechanisms of HBV replication and to screen for new anti-HBV agents. In this article, we summarize the establishment of such cell models and the identification of small molecules that inhibit the HBV entry process and discuss their future potential as a novel class of anti-HBV agents.
抗病毒药物的发展使得由疱疹病毒、人类免疫缺陷病毒和丙型肝炎病毒感染引起的慢性传染病得以控制。相比之下，针对乙型肝炎病毒（HBV）感染的抗病毒治疗仍有很大的改进空间。阻碍HBV研究进展的主要障碍之一是缺乏能够有效重现病毒增殖过程的细胞培养系统。最近，基于细胞系的HBV感染系统已被开发出来，这对于分析HBV复制机制和筛选新的抗HBV药物很有用。在本文中，我们总结了此类细胞模型的建立以及抑制HBV进入过程的小分子的鉴定，并讨论了它们作为新型抗HBV药物的未来潜力。
